References
- Chen C, Wilcoxen KM, Huang CQ, et al. (2004). Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure–activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists. J Med Chem 47:4787–98
- Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
- Gibaldi M, Perrier D. (1982). Pharmacokinetics. New York: Marcel Dekker
- Gilligan PJ, Clarke T, He L, et al. (2009). Synthesis and structure–activity relationships of 8-(Pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists. J Med Chem 52:3084–92
- Hakooz N, Ito K, Rawden H, et al. (2006). Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance. Pharm Res 23:533–9
- Hallifax D, Houston JB. (2006). Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724–6
- Hansch C, Bjoerkroth JP, Leo A. (1987). Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J Pharm Sci 76:663–87
- He L, Gilligan PJ, Zaczek R, et al. (2000). 4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF1 receptor antagonist. J Med Chem 43:449–56
- Holsboer F, Ising M. (2008). Central CRH system in depression and anxiety – evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583:350–7
- Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharm 47:1469–79
- Keller C, Bruelisauer A, Lemaire M, Enz A. (2002). Brain pharmacokinetics of a nonpeptidic corticotropin-releasing factor receptor antagonist. Drug Metab Dispos 30:173–6
- Logrip ML, Koob GF, Zorrilla EP. (2011). Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention. CNS Drugs 25:271–87
- Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350–9
- Paschos KA, Kolios G, Chatzaki E. (2009). The corticotropin-releasing factor system in inflammatory bowel disease: prospects for new therapeutic approaches. Drug Discov Today 14:713–20
- Seymour PA, Schmidt AW, Schulz DW. (2003). The pharmacology of CP-154,526, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev 9:57–96
- Stringer R, Nicklin PL, Houston JB. (2008). Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance. Xenobiotica 38:1313–29
- Tanaka E. (1999). Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 24:339–46
- Waxman DJ, Holloway MG. (2009). Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol 76:215–28
- Zorrilla EP, Koob GF. (2004). The therapeutic potential of CRF1 antagonists for anxiety. Exp Opin Invest Drugs 13:799–828